Selexys Pharmaceuticals will recruit around 30 healthy subjects in the trial.
The study will investigate the safety and pharmacology of SelG1 prior to advancement into a Phase II trial in patients with sickle cell disease.
Selexys president and CEO Scott Rollins said this Phase I study represents the first step in understanding the potential of SelG1 to address the unmet medical need in sickle cell disease and we are excited to initiate the clinical development of this novel compound.
"This Phase I trial represents a key milestone for Selexys as we transition from a preclinical to a clinical development stage biopharmaceutical company," Rollins said.